Beximco Pharmaceuticals Ltd.
BXP | IL
Overview
Corporate Details
- ISIN(s):
- US0885792061
- LEI:
- 213800IMBBD6TIOQGB56
- Country:
- Bangladesh
- Address:
- N/A
- Website:
- https://www.beximcopharma.com
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-13 17:10 |
Report Publication Announcement
Request of Extension to Publish Q1 Results
|
English | 11.2 KB | ||
| 2025-11-04 08:25 |
Regulatory Filings
Change of Name to Beximco Pharmaceuticals PLC.
|
English | 10.8 KB | ||
| 2025-10-27 16:53 |
Report Publication Announcement
Request of Extension to Publish Financial Results
|
English | 11.3 KB |
Automate Your Workflow. Get a real-time feed of all Beximco Pharmaceuticals Ltd. filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Beximco Pharmaceuticals Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Beximco Pharmaceuticals Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Develops myeloid cell-targeting immunotherapies for solid and hematological cancers.
Finland
FARN
Finland
FARN
Develops off-the-shelf iPSC cell therapies for cancer and autoimmune diseases.
United States of America
FATE
United States of America
FATE
Prevents chemotherapy-induced hearing loss in children with its sole product, PEDMARK®.
United States of America
FENC
United States of America
FENC
Clinical-stage biotech developing fibroblast cell therapies for chronic diseases.
United States of America
FBLG
United States of America
FBLG
Biopharma developing first-in-class therapies for cancer, anemia, and serious conditions.
United States of America
FGEN
United States of America
FGEN
Contract development & manufacturing of oral solids for pharma, nutraceutical & cosmetic sectors.
Italy
FF
Italy
FF
Provides nutritional supplements for sports nutrition, weight management, and general health.
United States of America
FTLF
United States of America
FTLF
A diversified firm in pharma distribution, plant-based wellness, and digital assets.
United States of America
FLGC
United States of America
FLGC
Develops fluorescent drugs to guide surgeons for more precise cancer removal and patient outcomes.
Denmark
FLUO
Denmark
FLUO
Develops cost-effective biosimilars for ophthalmology, immunology, and other chronic diseases.
Germany
FYB
Germany
FYB